Cardinal Health (NYSE: CAH), one of the nation's largest pharmaceutical distributors, reported a mixed fiscal fourth quarter on Tuesday, August 11, 2026, with an adjusted earnings beat offsetting a revenue shortfall. A robust full-year earnings outlook further buoyed investor sentiment.

CARDINAL HEALTH $CAH Q4'26 EARNINGS HIGHLIGHTS 🔹 Revenue: $63.7B (Est. $65B) 🔴; +6% YoY 🔹 Adj. EPS: $2.91 (Est. $2.42) 🟢; +40% YoY 🔹 Non-GAAP Oper Earnings: $935M (Est. $820M) 🟢; +30% YoY 🔸 IEEPA Tariff Refund: $100M operating profit impact; $0.31 EPS impact FY27 Guide:… pic.twitter.com/HbBlV1UQfE — Wall St Engine (@wallstengine) August 11, 2026

Q4 Financial Results

Adjusted EPS reached $2.91 for the quarter, surpassing the $2.42 analyst consensus by a wide margin and representing 40% year-over-year growth. The figure included a $0.31 per-share benefit from IEEPA tariff refunds, bringing the underlying adjusted EPS to $2.60. For a company whose core pharmaceutical distribution business operates on thin gross margins measured in the low single digits, operational efficiency gains and favorable generic drug economics have an outsized impact on profitability relative to topline results.

Revenue climbed 6% year over year to $63.67 billion but fell short of Wall Street's $65.15 billion estimate. Non-GAAP operating earnings totaled $935 million, beating the $820 million consensus and rising 30% year over year.

On a GAAP basis, net profit was $398 million, or $1.70 per share, up from $239 million, or $1.00 per share, in the prior-year quarter.

CAH shares declined 0.8% in premarket trading on Tuesday.

Segment Performance

The pharmaceutical segment delivered 6% revenue growth, fueled by higher volumes from existing customers and strong generic drug performance. Generic drug distribution has been a consistent profit driver for the Big Three wholesalers — Cardinal Health, McKesson, and Cencora — as brand-name drugs lose patent protection and lower-cost generics flow through the supply chain.

The global medical products and distribution segment was the weaker performer, with revenue declining 2%. The drop was attributed to lower distribution volumes and the recognition of expected tariff refund repayments to customers. This segment has been a strategic focus area for Cardinal, which has worked to streamline its medical device and supply operations after years of mixed performance.

Fiscal 2027 Guidance

For the new fiscal year, Cardinal Health issued adjusted EPS guidance of $12.40 to $12.60, representing 13% to 15% growth and comfortably exceeding the FactSet consensus of $12.08.

The company projected pharmaceutical revenue growth of 3% to 5% and medical products and distribution growth of 2% to 4%.

The outlook accounts for Cardinal's recent expansion into home care, including the acquisition of Strive Medical and a pending deal for AdaptHealth's diabetes business. The moves position Cardinal in the growing home-based healthcare market, where demand for in-home chronic disease management — particularly diabetes care — has expanded as payers and providers shift toward lower-cost care settings.

Additionally, Cardinal Health announced a new $4 billion revolving credit agreement extending through 2031, replacing three older credit facilities.